Skip to content

Medical-device intelligence

OZZ: Bordetella Pertussis Dna Assay System

FDA product code OZZ: Bordetella Pertussis Dna Assay System. View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
OZZ
FDA device name
Bordetella Pertussis Dna Assay System
Device class
2
Regulation number
866.3980
Medical specialty
Microbiology
Review panel
MI

FDA definition

A qualitative in vitro diagnostic assay intended to detect Bordetella pertussis DNA extracted from human respiratory specimens. Detection of Bordetella pertussis DNA aids in the diagnosis of Bordetella pertussis respiratory infection in conjunction with other clinical and laboratory testing in patients exhibiting signs and symptoms of upper respiratory tract infection.
Explore microbiology records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

9 clearance records and 2 recall records in the covered releases, across 7 source company names and 1 product codes. Dated history runs from Mar 25, 2014 to Nov 20, 2025.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202510
December 202500
January 202600
February 202600
March 202600
April 202600
May 202600
June 202600
July 202600
August 202600
September 202600
October 202600

Product codes represented

Code and FDA device nameClearancesRecalls
OZZ · Bordetella Pertussis Dna Assay System92

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

11 matching records
Device / recordCompany in FDA recordSourceSource date
cobas liat Bordetella panel nucleic acid testK243753 · OZZRoche Molecular Systems, Inc.510(k)Nov 20, 2025FDA decision date
Brand Name: Solana Bordetella Complete Assay Product Name: Solana Bordetella kit Model/Catalog Number: M308 Software Version: not applicable Prod…Z-1948-2025 · OZZOrtho-Clinical Diagnostics, Inc.RecallJun 11, 2025FDA classification date
Aries Bordetella Assay, REF 50-10037, UDI # 00840487101452Z-2282-2019 · OZZLuminex CorporationRecallAug 15, 2019FDA classification date
Simplexa Bordetella Direct, Simplexa Bordetella Positive Control PackK183223 · OZZDiasorin Molecular, LLC510(k)Dec 19, 2018FDA decision date
Simplexa Bordetella Direct, Simplexa Bordetella Positive Control PackK173498 · OZZDiasorin Molecular, LLC510(k)Aug 13, 2018FDA decision date
Solana Bordetella Complete AssayK181029 · OZZQuidel Corporation510(k)Jul 15, 2018FDA decision date
ARIES Bordetella Assay; ARIES Bordetella Assay Protocol File KitK163626 · OZZLuminex Corporation510(k)May 2, 2017FDA decision date
Great Basin Bordetella Direct TestK170284 · OZZGreat Basin Scientific, Inc.510(k)Mar 31, 2017FDA decision date
illumigene Pertussis DNA Amplification AssayK152285 · OZZMeridian Bioscience, Inc.510(k)Nov 10, 2015FDA decision date
AmpliVue Bordetella AssayK143206 · OZZQuidel Corporation510(k)Dec 10, 2014FDA decision date
ILLUMIGENE PERTUSIS DNA AMPLIFICATION ASSAY, ILLUMIGENE PERTUSSIS EXTERNAL CONTROL KIT, ILLUMIPRO-10 AUTOMATED ISOTHERMAK133673 · OZZMeridian Bioscience, Inc.510(k)Mar 25, 2014FDA decision date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 21, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗